Moving mRNA–LNP therapeutics towards the clinic: overcoming myths and misconceptions to solve the specificity challenge

Nucleic Acid Insights 2024; 1(4), 177–184

DOI: 10.18609/nai.2024.022

Published: 21 May
Ansgar Santel, Jörg Kaufmann

The COVID-19 pandemic catapulted mRNA into the spotlight—but what wider impacts did this success have on the field? David McCall, Senior Editor, Nucleic Acid Insights, speaks to Ansgar Santel, CEO and Jörg Kaufmann, CSO, of Pantherna Therapeutics about the latest developments in the mRNA–LNP space, tackling myths and safety concerns surrounding cationic lipids, and Pantherna’s approach to solving the issue of moving beyond hepatocyte targeting.